4 February 2010

New computational tool for structure-based drug design

Science|Business

Research lead

Many human tumours express indoleamine 2,3-dioxygenase (IDO), an enzyme which prevents the body from mounting an immune response to the tumour mediates an immune-escape in several cancer types.

Now researchers in the Molecular Modelling group at the Swiss Institute of Bioinformatics (SIB) and Benoît J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) in Brussels, have developed an approach to generating new IDO inhibitors by computer-assisted structure-based drug design.

The docking algorithm EADock, used for this project, has been developed over the past eight years by the Molecular Modelling Group. This algorithm will soon be made available to the scientific community worldwide.

The scientists say they...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.